AOD-9604 is a synthetic peptide derived from a specific region of human growth hormone (HGH). Researchers developed it to investigate whether certain metabolic effects associated with HGH could be separated from its growth-promoting activity.
Over the years, AOD-9604 has been studied for its possible effects on fat metabolism, body composition, and metabolic health. These investigations have led to growing interest in AOD-9604 dosage, including how much was used in clinical studies and whether an effective dosing schedule has been established.
There is currently no FDA-approved AOD-9604 dosage for weight management, fat reduction, or any other medical condition. Although clinical trials have examined different doses, the available evidence has not established a safe and effective therapeutic regimen.
This guide explains the dosages studied in clinical research, the differences between oral and injectable administration, and the safety considerations that matter when evaluating AOD-9604.
What Is AOD-9604?
AOD-9604 stands for Anti-Obesity Drug 9604. It is a modified peptide based on amino acids 177–191 of human growth hormone, with an additional tyrosine residue.
Unlike full-length HGH, AOD-9604 was designed to investigate selected metabolic pathways without substantially stimulating the growth-related pathways associated with HGH.
Early laboratory and animal studies investigated whether the peptide could influence two important processes:
- Lipolysis: The breakdown of stored triglycerides into fatty acids and glycerol.
- Lipogenesis: The process through which the body synthesizes and stores fat.
Some preclinical studies reported changes in fat metabolism following AOD-9604 administration. However, promising animal findings have not translated into consistent clinical benefits in humans.
AOD-9604 is also different from medications that have received FDA approval for chronic weight management. Its clinical development for obesity was discontinued after a larger trial failed to demonstrate significant effectiveness.
What Is the Recommended AOD-9604 Dosage?
There is no medically established or FDA-approved dosage for AOD-9604.
Clinical investigators have evaluated several doses through oral administration and intravenous infusion. However, the amounts used in these experiments should not be interpreted as recommended treatment doses.
The following table summarizes selected dosing ranges investigated during human clinical development.
| Clinical study | Dosage investigated | Administration |
|---|---|---|
| Early Phase I studies | 25–400 mcg/kg | Intravenous |
| Early oral studies | 9–54 mg | Oral |
| 12-week clinical trial | 1–30 mg daily | Oral |
| 24-week clinical trial | 0.25–1 mg daily | Oral |
These dosages were selected for controlled research purposes. They do not establish an optimal dose for clinical use.
The distinction is important because finding a tolerable dose in a clinical trial is not the same as demonstrating that the dose produces a meaningful therapeutic benefit.
AOD-9604 Dosage in Clinical Studies
The clinical development of AOD-9604 involved multiple trials conducted between 2001 and 2006.
A 2013 paper published in the Journal of Endocrinology and Metabolism reviewed six randomized, double-blind, placebo-controlled studies involving 893 participants.
These trials investigated the peptide’s tolerability, metabolic effects, and possible effectiveness in managing obesity.
Early Clinical Trials: Establishing Initial Safety
The first studies primarily focused on how AOD-9604 behaved following administration.
Researchers investigated intravenous doses ranging from 25 to 400 mcg per kilogram of body weight.
Other early trials evaluated oral doses of 9, 27, and 54 mg.
The purpose was to examine short-term tolerability, metabolic responses, and potential changes in markers associated with growth hormone activity.
These studies did not establish an effective therapeutic dose.
The 12-Week AOD-9604 Study
A subsequent 12-week study evaluated daily oral doses ranging from 1 mg to 30 mg.
A published review reported that participants receiving 1 mg daily experienced an average weight reduction of approximately 2.6 kg, compared with 0.8 kg in the placebo group.
However, the results were not consistently dose-dependent.
For example, participants receiving 10 mg daily did not demonstrate greater weight reduction than those receiving the lower 1 mg dose.
This raised questions about whether increasing the amount of AOD-9604 produced additional therapeutic benefits.
Although these early results generated interest, they did not provide sufficient evidence to establish an effective dosage.
The 24-Week Clinical Trial
One of the largest AOD-9604 studies evaluated oral doses of 0.25 mg, 0.5 mg, and 1 mg daily over 24 weeks.
The trial involved approximately 500 participants.
Researchers compared the outcomes of the different dosing groups with those receiving placebo.
Unfortunately, the study did not demonstrate a statistically significant weight-loss benefit compared with placebo.
As a result, the development program for AOD-9604 as an obesity treatment was discontinued in 2007.
This remains one of the most important findings when discussing the possibility of an effective AOD-9604 dosage.
The available human evidence does not establish any AOD-9604 dose as reliably effective for weight management.
Oral vs. Injectable AOD-9604: Does the Dosage Differ?
AOD-9604 has been investigated through different administration routes. However, the evidence supporting each method varies considerably.
Oral AOD-9604
Oral administration accounts for most of the longer-duration human clinical research on AOD-9604.
Researchers examined oral doses ranging from fractions of a milligram to several milligrams daily.
The largest studies used oral formulations over 12- and 24-week periods.
Although the published safety review reported generally favorable tolerability in these settings, the studies did not establish consistent therapeutic effectiveness.
Consequently, no approved oral dosing schedule exists.
Subcutaneous AOD-9604 Injections
Subcutaneous administration involves delivering a substance into the fatty tissue beneath the skin.
Some online peptide resources describe AOD-9604 injection protocols involving several hundred micrograms daily.
However, these protocols should not be confused with clinically validated dosing guidelines.
The major human clinical trials of AOD-9604 primarily investigated oral and intravenous administration.
Published controlled human studies have not established an effective subcutaneous injection dosage.
This creates several unanswered questions, including:
- How subcutaneous administration affects absorption and drug exposure.
- Whether injected AOD-9604 produces clinically meaningful benefits.
- Whether repeated injections increase immunogenicity or other safety risks.
- What dose or treatment duration, if any, would be appropriate.
Because these questions remain unresolved, oral trial dosages cannot simply be converted into recommended injection doses.
How Long Was AOD-9604 Used in Clinical Research?
Treatment duration is another important consideration.
Early AOD-9604 studies were relatively short and focused on immediate tolerability and metabolic responses.
Later trials evaluated daily administration over 12 and 24 weeks.
These longer trials provided more information about the peptide’s short- and medium-term safety profile.
However, they did not demonstrate sufficient effectiveness to support approval.
There is also limited information about the consequences of long-term exposure beyond the periods investigated in clinical studies.
Therefore, no evidence-based AOD-9604 treatment cycle or recommended duration has been established.
Does a Higher AOD-9604 Dosage Produce Better Results?
Not necessarily.
The relationship between dosage and treatment response is an important part of drug development.
For some medications, increasing the dose produces a greater biological response until a certain threshold is reached.
AOD-9604 did not demonstrate a clear, consistent dose-response relationship in its clinical obesity studies.
The 12-week trial provides an example.
Participants receiving 1 mg daily showed a larger average weight reduction than those receiving some higher doses.
These observations indicate that increasing the amount administered did not consistently improve the measured outcomes.
The subsequent 24-week trial also failed to demonstrate significant effectiveness.
Together, these findings mean there is no scientific basis for assuming that higher AOD-9604 doses produce better weight-management outcomes.
Increasing exposure to an investigational compound may instead introduce additional safety concerns without proven benefits.
What Does Research Say About AOD-9604 Safety?
The safety profile of AOD-9604 has been examined in both human and preclinical studies.
A 2013 analysis of six clinical trials reported that AOD-9604 was generally well tolerated at the doses and routes investigated.
Researchers specifically evaluated several biological markers associated with human growth hormone.
IGF-1 Levels
Insulin-like growth factor 1 (IGF-1) is an important hormone involved in growth and tissue development.
Full-length HGH can increase circulating IGF-1 concentrations.
However, clinical investigations reported that AOD-9604 did not significantly increase serum IGF-1 levels.
These findings suggest that the peptide does not reproduce all the biological actions of full-length HGH.
Glucose Metabolism
Researchers also investigated whether AOD-9604 influenced carbohydrate metabolism.
In the reviewed studies, oral glucose tolerance testing did not demonstrate the same adverse effects on glucose regulation sometimes associated with HGH treatment.
However, these results do not establish safety for every population, dosing schedule, or administration route.
Immunogenicity
Immunogenicity refers to the possibility that a substance may trigger an immune response.
The 2013 clinical analysis did not detect anti-AOD-9604 antibodies in the participants selected for antibody testing.
Nevertheless, the FDA has subsequently identified concerns about possible immune reactions associated with compounded AOD-9604, particularly where peptide impurities, aggregation, or different administration routes may affect safety.
The absence of a concerning signal in an earlier trial does not eliminate these risks.
Potential Side Effects and Safety Concerns
Although the earlier clinical trials reported relatively favorable short-term tolerability, AOD-9604 has not undergone the full regulatory review required for an approved medication.
The FDA has identified several concerns involving compounded preparations containing AOD-9604.
These include:
- Potential immunogenicity with certain administration routes.
- Peptide-related impurities and aggregation.
- Limited information about the safety of subcutaneous administration.
- Incomplete characterization of the active pharmaceutical ingredient.
- Insufficient evidence to establish clinical effectiveness.
FDA reviews have also discussed reported adverse events, although a causal relationship with AOD-9604 has not always been established.
These limitations are especially important because the safety data from oral clinical trials cannot automatically establish the safety of injectable formulations.
Patients should not assume that AOD-9604 is safe simply because it is derived from part of a naturally occurring hormone.
Is AOD-9604 FDA-Approved?
No. As of October 2026, AOD-9604 is not FDA-approved for weight management, fat reduction, hormone replacement, or any other therapeutic indication.
It also does not have an FDA-approved dosage or prescribing label.
In December 2024, the FDA’s Pharmacy Compounding Advisory Committee considered AOD-9604-related substances as part of the federal review process for bulk ingredients used in pharmacy compounding.
FDA’s assessment raised concerns about limited evidence of clinical effectiveness, inadequate characterization, and unresolved safety issues.
The agency’s published information on bulk substances also identifies potential significant safety risks associated with compounded AOD-9604.
Importantly, the fact that a peptide has appeared in clinical research does not mean it is authorized for routine prescribing or compounding.
Clinicians and patients should verify current regulatory requirements before considering any investigational or compounded substance.
AOD-9604 Dosage: Questions Patients Frequently Ask
What is the standard daily dosage of AOD-9604?
There is no approved standard daily dosage. Clinical trials investigated different oral doses, including 0.25 mg, 0.5 mg, and 1 mg daily, but these studies did not establish an effective therapeutic regimen.
Is 300 mcg of AOD-9604 an effective dose?
Some online sources discuss 300 mcg as part of informal injection protocols. However, controlled human clinical evidence has not established this amount as safe or effective for subcutaneous administration.
Can AOD-9604 be administered every day?
Daily administration was investigated in oral clinical studies lasting up to 24 weeks. This does not mean daily administration is appropriate or recommended outside a controlled research setting.
What is the best time to take AOD-9604?
There is insufficient clinical evidence to identify an optimal administration time. Claims that morning dosing, nighttime dosing, or fasting administration improves results have not been adequately validated in human trials.
How long does AOD-9604 take to work?
There is no established timeline for therapeutic results because clinical trials have not demonstrated consistent effectiveness. Early studies observed changes in some metabolic measures, but the larger trial failed to confirm a meaningful weight-loss benefit.
Is AOD-9604 the same as human growth hormone?
No. AOD-9604 is a modified fragment derived from the C-terminal region of human growth hormone. It does not reproduce the full biological activity of HGH and is not an FDA-approved replacement for growth hormone therapy.
Can AOD-9604 be combined with other peptides?
There is insufficient clinical evidence to establish the safety or effectiveness of combining AOD-9604 with other investigational peptides. Such combinations may introduce additional risks and unpredictable interactions.
Final Thoughts: Is There an Optimal AOD-9604 Dosage?
AOD-9604 has been studied through several clinical trials, but researchers have not identified a dosage that consistently produces meaningful therapeutic benefits.
Early investigations suggested possible metabolic activity, and published safety analyses reported generally favorable tolerability in selected research populations.
However, the larger 24-week clinical trial failed to demonstrate significant weight-loss effectiveness.
Questions also remain regarding the safety and effectiveness of commonly discussed subcutaneous injection protocols.
For these reasons, there is currently no evidence-based optimal AOD-9604 dosage for clinical treatment.
At Optimal HRT, we believe decisions about metabolic health and hormone-related care should be guided by reliable clinical evidence, appropriate medical evaluation, and treatments with established safety and effectiveness.
Patients interested in weight management or metabolic health should consult a qualified healthcare professional to discuss evidence-based options suited to their individual needs.
Scientific References
- Stier H, Vos E, Kenley D. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism, 3(1–2), 7–15.
https://doi.org/10.4021/jem157w - Moré et al. (2014). Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. Journal of Endocrinology and Metabolism.
https://www.jofem.org/index.php/jofem/article/view/213/278 - Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy. (2011). Review of anti-obesity drug development, including AOD-9604 clinical findings.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3136748/ - U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks - U.S. Food and Drug Administration. (2024). Pharmacy Compounding Advisory Committee Meeting: AOD-9604-Related Bulk Drug Substances.
https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-meeting-time-and-public-participation-information-december-4-2024-meeting-pharmacy
Medical Disclaimer: This article on OptimalHRT is for educational purposes only. AOD-9604 is an investigational peptide and is not FDA-approved for therapeutic use. The dosages discussed reflect historical research, not recommendations for personal administration. This information should not replace medical advice from a licensed healthcare professional.
2 Responses